New Delhi: According to sources, Bharat Biotech's Covaxin showed 77.8% efficacy after the pharma regulator's Subject Expert Committee (SEC) reviewed its Phase III study data on Tuesday.
The Hyderabad-based COVID vaccine manufacturing company had submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend.
Bharat Biotech's 'pre-submission meeting with the World Health Organization (WHO) will take on Wednesday for the approval of Covaxin.
Covaxin is one of the three vaccines which are currently being used in India. The vaccine's phase III data has been questioned several times. Therefore, the data that determines the vaccine's efficacy is critical.
The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR).
#RSSIsHere Ready For Selfless Service | RSS India | Rastriya Sewa | Latest 2021 | New | Trending Crisis comes uncalled, but sons of the soil, are the one who hold the nation first irrespective of the situation. The Rashtriya Swayamsevak Sangh has steadfastly performed its duties selflessly. The sangh is also preparing itself for the third wave of Corona and work can be seen in every part of the country. Download Organiser Mobile App: https://play.google.com/store/apps/details?id=org.organiser...
Vice President urges youth to visit ancient monuments to learn about India’s great past. The Vice President, Shri M. Venkaiah Naidu, stressed the need to prioritise mental well-being as a public health issue in the wake of the COVID pandemic. Observing that fast-paced sedentary lifestyles can cause stress and anxiety among people, he suggested that a spiritual outlook on life can relieve tensions. He urged religious leaders to take the message of spirituality and ...